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compared to its sporadic counterpart, it is immediately
clear that it follows a different histological sequence
(Seril et al., 2003; Itzkowitz and Yio, 2004), starting in
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the inflamed mucosa as a hyperplastic lesion, to developUppsalalaan 8
through (flat) dysplasia into adenocarcinoma. This isUtrecht 3584 CT
sometimes summarized as the “inflammation-dyspla-The Netherlands
sia-carcinoma” sequence. Although these differences
may suggest divergent pathogenic pathways, molecular
studies indicate that the transformation process is
largely shared between sporadic and UC-associated co-Chronic inflammation and cancer are closely associ-
lorectal cancer. The relative order in which mutations inated in the intestine. Anti-inflammatory medication
genes such as APC, P53, SMAD4, or K-ras may differ,reduces intestinal neoplasia, while colorectal cancer
yet these mutations are observed with comparable fre-incidence is increased in ulcerative colitis. Cyclooxy-
quencies in both disease entities. It thus appears rea-genases are key to both diseases, yet the molecular
sonable to consider the two forms of colorectal cancer,basis of the association remains incompletely under-
once initiated, as a single disease entity.stood. Two recent Cell (Greten et al., 2004; Rakoff-
Multiple animal models have been established for theNahoum et al., 2004) papers illuminate roles of Toll-
dissection of the effects of inflammatory mediators andlike receptors and the NF-B pathway in the control
anti-inflammatory drugs on UC-associated, hereditary,of epithelial homeostasis in health and disease.
and sporadic forms of colorectal cancer (for an exhaus-
tive overview, see Oshima and Taketo, 2002; KoehneUlcerative colitis (UC) is a common chronic inflammatory
and Dubois, 2004). It is important to note that thesedisease of unknown etiology, which affects the mucosa
models are somewhat limited in their interpretation ofof the large bowel. UC is associated with an elevated
the human condition, since the cause of UC remainsrisk for colorectal cancer, which is in the order of 10-
unknown. Roughly, the models can be divided into twofold greater than in the general Western population (re-
groups, one in which colitis is induced by chemicalviewed in Itzkowitz and Yio, 2004; Seril et al., 2003). The
means and one in which colitis develops due to geneticrisk of developing cancer increases strongly with the
manipulation (reviewed in Seril et al., 2003; Itzkowitzduration and the extent of the disease. Indeed, UC ranks
and Yio, 2004). The most widely used chemical inductionamong the top three high-risk conditions for colorectal
model involves the administration of dextran sulfate so-cancer, together with the Familial Adenomatous Polypo-
dium (DSS) in the diet of rodents. DSS is a synthetic,sis (FAP) and Hereditary Nonpolyposis Colorectal Can-
sulfated polysaccharide that causes acute and chroniccer (HNPCC) syndromes. Unlike the latter two conditions
colitis (reviewed in Seril et al., 2003). Carcinomas withthat have a well-understood genetic etiology, it is un-
involvement of the APC pathway are reportedly inducedlikely that the association of UC with colorectal cancer
by DSS in rats, hamsters, and mice. DSS treatment of
results from an underlying genetic cancer predisposi-
the APC mutant min mouse as well as the combination
tion. Rather, it is now commonly believed that it is the
of DSS treatment with a carcinogen, such as azoxymeth-
chronic inflammation process itself that is responsible ane (AOM), represent extremely efficient ways to gener-
for the occurrence of neoplastic transformation of the ate adenocarcinomas of the intestine. In most chemical
intestinal epithelium (Itzkowitz and Yio, 2004). An addi- models, chronic inflammation by disruption of the muco-
tional link exists between inflammation and colorectal sal barrier function and the concomitant immune hyper-
cancer. Epidemiological studies have indicated that the activation by the microflora is presumed to represent
regular administration of nonsteroidal anti-inflammatory the key event that creates a microenvironment that is
drugs (NSAIDs) lowers mortality from sporadic colo- permissive for the progressive transformation of colon
rectal cancer and causes regression of adenomas in epithelial cells. The genetic models commonly affect
patients with FAP (reviewed in Oshima and Taketo, genes that regulate the immune response (Seril et al.
2002). The specific molecular mechanism behind this 2003), creating a state of chronic hyperactivity of the
phenomenon remains unknown. adaptive immune system. As with the chemically in-
Sporadic colorectal cancer is probably the best un- duced colitis models, efficient development of colitis
derstood solid malignancy in man. Histologically, it requires the mucosa-associated microflora, as demon-
progresses in a stepwise fashion, termed the adenoma- strated by comparing mice raised under specific-patho-
carcinoma sequence. As originally proposed by Fearon gen-free and germfree conditions (Schuppler et al., 2004
and Vogelstein (1990), defined molecular alterations un- and references therein).
derlie these progressive changes in histology. Typically, The prevailing view on the association of UC and can-
the neoplastic lesions first present as aberrant crypt cer involves an indirect mechanism, in which inflamma-
foci or microadenomas and develop through a large tion of the submucosa, induced by direct contact with
adenoma-stage into carcinoma in situ and invasive ade- the intestinal microflora, promotes tumor outgrowth in
nocarcinoma. When UC-associated colorectal cancer is the overlying epithelium. Two recent papers in Cell
(Greten et al., 2004; Rakoff-Nahoum et al., 2004) provide
support for an alternative model in which inflammatory*Correspondence: clevers@niob.knaw.nl
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signaling in the epithelial cells proper results in their
inappropriate survival and transformation. Activated NF-
B, the key regulator of inflammation, is present in many
solid tumors and cell lines derived thereof (reviewed
in Amit and Ben-Neriah, 2003). Noting this, Karin and
colleagues (Greten et al., 2004) set out to study the
role of the NF-B pathway in a mouse model for UC-
associated colorectal cancer. To this end, they deleted
an essential component of the pathway, the IKK kinase,
either in all myeloid cells or in the intestinal epithelial
cells. Disruption of the NF-B pathway in myeloid cells
essentially confirmed a scenario by which inflammation
creates a signaling niche in which transformed cells
prosper. When the genetically modified mice were sub-
jected to a chemically induced colitis/carcinogen proto-
col (DSS/AOM, see below), the numbers and size of
the adenomas were substantially reduced. As expected,
induction of inflammatory mediators including COX-2
was substantially decreased. The authors concluded
that the lower tumor incidence was due to the loss of Figure 1. Commensals Provide Survival Signals through TLR Re-
ceptorsproduction of tumor-promoting paracrine factors.
The commensal intestinal flora activates Toll-like Receptors (TLR)The unexpected result came when the NF-B pathway
on the luminal surface of intestinal epithelial cells (Rakoff-Nahoumwas deleted in intestinal epithelial cells. In a previous
et al., 2004). This interaction triggers the activity of intracellularstudy, the authors had found that IKK removal from
signaling pathways, such as the IKK-/NF-B cascade, providing
these cells did not affect normal homeostasis of the potent survival signals for the epithelial cell (Greten et al., 2004).
epithelium. However, the mutant epithelium was found Figure courtesy of Geert van Eldik.
to be much more sensitive to ischemia-reperfusion-
induced apoptosis, implying a cell-autonomous role for
the NF-B pathway in epithelial cell survival (Chen et TLR2 or TLR4. In all cases, this unexpectedly led to
al., 2003). Accordingly, the mutant epithelium appeared increased susceptibility to DSS-induced colonic injury.
more susceptible to DSS-induced histological damage The authors went on to demonstrate that—under physi-
than control epithelium, while the production of many ological conditions—commensal bacteria activate TLRs,
inflammatory mediators was actually enhanced. Despite and that the resulting TLR activity provides protection
this, the colitis-associated tumor incidence in the DSS/ from colitis-induced damage. Since the authors did not
AOM model was greatly reduced. The authors then went apply cell type-specific gene ablation, it remains to be
on to show that an active NF-B pathway contributes formally demonstrated in which cell type TLR signaling
to tumor formation by providing antiapoptotic survival normally acts to enhance epithelial integrity. Yet, the
signals to the epithelial cells. While the exact molecular data fit best with a model in which recognition of bacte-
mechanism of this effect remains to be detailed, the rial products occurs by TLRs expressed on enterocytes,
study suggests that IKK acts through suppression of residing in an intact epithelial sheet. These activated
the mitochondrial apoptosis pathway by induction of TLRs would then mediate a cell-autonomous cell-sur-
the NF-B target gene Bcl-xL. vival response. Of note, the major signaling pathway
What could be the nature of the signal that triggers downstream of TLRs and MyD88, conserved from fly to
this epithelial NF-B survival pathway? Rakoff-Nahoum man, is the NF-B pathway (Beutler, 2004). The data of
et al. (2004) may provide a clue by showing that com- the recent Karin and Medzhitov studies can be inte-
mensal bacteria can activate a “cell-survival” pathway grated into a simple model (Figure 1) in which the com-
downstream of Toll-like receptors (TLRs). It had long mensal flora releases TLR ligands, e.g., lipopolysaccha-
been known that the resident microflora of the intestinal rides. These ligands trigger the TLR/MyD88/ NF-B
tract confers many benefits to intestinal physiology, in- pathway, providing survival signals to the enterocyte.
cluding trophic effects on the epithelium (Hooper and Cell-Autonomous Effects of Inflammation
Gordon, 2001 and references therein). Medzhitov and Pathways in Intestinal Epithelium?
colleagues wondered whether Toll-like receptors (TLRs) The previously published literature overwhelmingly sup-
that play a crucial role in host-defense could respond ports a scenario in which inflammation promotes (rather
to commensal bacteria. TLRs are pattern-recognition than initiates) carcinogenesis in a non-cell-autonomous
receptors that detect common microbial ligands. Proto- fashion. Loss of epithelial barrier function would lead to
typic examples of these ligands are lipopolysaccharides direct contact between the intestinal microflora and the
and lipoteichoic acid (LTA), recognized by TLR4 and TLR2 immune system. The resulting activity of inflammatory
respectively (Takedo et al., 2003). Curiously, pathogenic mediators, such as COX-2, would then create a tumor-
as well as commensal bacteria produce these ligands. promoting environment in which transformed epithelial
Rakoff-Nahoum et al. (2004) used mice deficient in cells thrive more optimally. Strong genetic support for
TLR signaling due to a deletion of the central adaptor this indirect model comes from observations made in
mice mutant for the major targets of NSAIDs, i.e., theprotein MyD88. Alternatively, they used mice lacking
Minireview
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colorectal cancer (Figure 2). Commensal bacteria con-
stitutively activate the NF-B pathway through TLRs
expressed on epithelial cells, supporting cell survival
and protecting the epithelium from injury. When stimu-
lated in transformed epithelial cells, this pathway accel-
erates tumor development in a cell-autonomous fashion.
This mechanism complements the non-cell-autono-
mous inflammation scenario, in which mediators pro-
duced by inflamed stroma promote tumorigenesis.
Moreover, the existence of the cell-autonomous path-
way may also explain the beneficial effects that are seen
with anti-inflammatory treatment of sporadic colorectal
cancer, in which no overt inflammation appears present.
If confirmed, future therapeutic strategies for colorectal
cancer may take advantage of this cell-autonomous cell-
survival role of TLRs and the NF-B pathway in intesti-
nal epithelium.
The studies raise some immediate questions. TLR sig-
naling by commensal bacteria appears to exert protec-
tive effects on the epithelium, while TLR signaling initi-
ated by pathogens leads to inflammation. How are these
two broad categories of microorganisms distinguished
by the TLR pattern recognition receptors? One possibil-
ity may be that the cell type that recognizes the TLR
ligands determines the outcome of the interaction. TLR
signaling in intact epithelial cells would thus lead to the
previously observed trophic response of the epithelial
sheet to commensals. On the other hand, direct interac-
tion of bacterial products with submucosal inflammatory
cells would only occur when the epithelium is damaged
and would thus be associated with the presence of
pathogenic bacteria. Another question that can now be
answered relates to the identity of the target(s) responsi-
ble for the protective effects of NSAIDs in colorectal
cancer. With the novel information discussed here, it is
likely that the transformed epithelial cell, and not the
stromal environment, represents the direct target for
anti-inflammatory drug treatment. From this perspec-
Figure 2. Two NFB Pathways Promote Tumorigenesis tive, it is intriguing that several NSAIDs have been dem-
Physical, chemical, or microbial insults cause mutations (trans- onstrated to inhibit the kinase activity of IKK (Yin et
forming epithelial cells), and break epithelial integrity (exposing un- al., 1998; Yamamoto et al., 1999)
derlying cell layers). The intestinal flora triggers the NF-B pathway
in macrophages to release proinflammatory agents such as prosta-
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Note Added in Proof
The role of the NF-B pathway in linking chronic inflammation and
cancer is not restricted to the gut. In an online paper in Nature
(“NF-B functions as a tumour promoter in inflammation-associated
cancer” Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit,
S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., and
Ben-Neriah, Y., published online August 25, 2004 doi:10.1038/
nature02924), Ben-Neriah and colleagues study MDR-2 knockout
mice as a model for chronic hepatitis-associated hepatocellular
carcinoma. Using a transgenic approach, the authors demonstrate
that hepatocytes require an intact NF-B pathway to be protected
against apoptosis and to progress to hepatocellular carcinoma in
a chronic inflammation setting.
